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doi:10.1016/j.jtcvs.2003.12.014266 The Journal of Thoracic and CardioObjectives: We sought to determine whether changes in quality of life at 18 months
following aortic valve replacement differ depending on the use of tissue valves or
mechanical valves.
Methods: We prospectively studied 73 patients with tissue valve replacements and
53 patients with mechanical valve replacements performed from April 1998 through
March 1999 at Yale-New Haven Hospital. Quality of life was measured at baseline
and at 18 months using the Medical Outcomes Trust Short Form 36-Item Health
Survey.
Results: Baseline unadjusted mean quality-of-life scores were lower in tissue valve
recipients than in mechanical valve recipients and, for both groups, were generally
lower than US population norms. At 18 months postoperatively, quality-of-life
scores were greatly improved in both groups and were comparable to population
norms (ie, within one-half a standard deviation). After adjusting for baseline quality
of life, age, and other prognostic factors in an analysis of covariance, improvements
in quality-of-life scores for tissue valve recipients versus mechanical valve recipi-
ents were similar. Of 10 (8 domains and 2 summary) scales examined, the only
significant difference between the 2 groups was for the improvement in role
limitations due to physical problems (Role Physical), which was more favorable in
patients with mechanical valve implants (P  .04).
Conclusions: The use of tissue valve implants versus mechanical valve implants has
little influence on improvement in quality of life at 18 months following aortic valve
replacement. Thus, decisions about whether to choose a tissue valve or mechanical
valve implant should depend upon other factors such as rates of complications and
differences in the life span of the implants.
Approximately 79,000 cardiac valve surgical procedures are per-formed annually in the United States.1 Aortic valve replacement isthe most common valve surgical procedure. Tissue or mechanicalvalves are implanted as substitutes for affected valves. The choiceof a tissue versus mechanical valve implant involves a trade-offbetween the better durability of mechanical valves and the lower
rate of anticoagulant-related complications associated with tissue valves.2-4
In current surgical practice, tissue valves are generally recommended for older
patients, as the life span of the tissue implant is less of an issue in this group. In
addition, the lower incidence of anticoagulant-related complications and slightly
vascular Surgery ● August 2004
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type of implant make it an attractive option for older or
high-risk patients who typically have more comorbidities
and more advanced heart disease. However, as the long-
term consequences of cardiac valve surgery extend beyond
postoperative complications or survival, improvement in
quality of life (QOL) is receiving more attention as an
important goal of surgery.5-8 Relatively little is known
about changes in QOL after aortic valve surgery and, more
specifically, about differences in improvement in QOL at-
tributed to the type of implant used. Given the differences in
valve characteristics, complications, and reliability, im-
provement in QOL might differ when tissue or mechanical
implants are used, and this information would assist sur-
geons and patients in choosing between the 2 types.
Most of the previous studies assessing the impact of
implant type on change in QOL have been cross-sectional,
thus being limited to postoperative assessment of QOL as
opposed to changes in QOL from baseline.5-7 Additionally,
the 1 prospective cohort study9 had only short-term (3
months) follow-up. Other limitations included relatively
small sample sizes9 and inclusion of only younger patients.7
Accordingly, the main purpose of this prospective study
was to determine if there are differences in changes in QOL
scores at 18 months postoperatively in tissue and mechan-
ical valve recipients. An additional aim was to compare
mean baseline and postoperative QOL scores in patients
with these 2 types of implants with those of age- and
gender-adjusted US population norms.
Methods
Study Design and Population
We used a prospective cohort study design. Consecutive patients
(n  189) undergoing isolated aortic valve or simultaneous aortic
valve-coronary artery bypass graft (CABG) procedures at Yale-
New Haven Hospital, New Haven, Connecticut, from April 1,
1998, through March 30, 1999, were identified for enrollment.
After consent, baseline questionnaires were completed by patients
during the first week after surgery. Baseline questions were related
to their functioning a month before surgery. Postoperative ques-
tionnaires were mailed to patients 18 months after the surgical
procedure. The study was approved by the Human Investigation
Committee of Yale University.
Measurement of QOL
We used the Medical Outcomes Trust Short Form 36-Item Health
Survey (SF-36), a survey with established overall reliability and
validity,10,11 to evaluate QOL. Several recent studies have also
demonstrated its validity specifically in cardiovascular re-
search.12,13
The SF-36 consists of 36 questions, grouped into 8 multi-item
domains, measuring different aspects of daily life described by
Bungay and Ware14:
1. Physical Functioning (PF) represents limitations in lifting,
climbing, bending, kneeling, walking, or running.
The Journal of Thoraci2. Role Physical (RP) represents a degree of physical health for
which a person performs activities typical for the specific age
and social responsibility, such as a job, community activities,
and volunteer work.
3. Bodily Pain (BP) represents the intensity and duration of
bodily pain and limitations in activities due to pain.
4. General Health (GH) represents the beliefs and evaluations
of a person’s overall health.
5. Vitality (VT) is a measure of feelings of energy, pep, fatigue,
and tiredness.
6. Social Functioning (SF) represents the ability to develop,
maintain, and nurture mature social relationships (including
family, friends, and spouse).
7. Role Emotional (RE) represents personal feelings about job
performance or work or other activities.
8. Mental Health (MH) represents a person’s emotional, cog-
nitive, and intellectual status.
Additionally, we used 2 meta-scores of the SF-36, the Physical
Component Summary (PCS) and the Mental Component Summary
(MCS). They combine 8 multi-item domains and represent global
physical functioning and global mental functioning.15 We com-
pared age-adjusted US population norms with QOL following
surgery.16,17
Demographic and Clinical Information
Detailed demographic and clinical information was abstracted
from medical records using Society of Thoracic Surgery forms and
definitions.18 Demographic variables included age and gender.
Comorbidities included peripheral vascular disease (PVD), chronic
obstructive pulmonary disease, diabetes, and hypertension. Heart
disease–related variables were history of congestive heart failure,
New York Heart Association (NYHA) functional class (III-IV
versus I-II), angina, ejection fraction, cardiomegaly, chronic atrial
fibrillation, previous myocardial infarction (MI), aortic stenosis,
and reoperation. Procedure-related variables were implant type
(tissue, mechanical) and procedure type (isolated valve replace-
ment vs simultaneous valve and CABG).
Statistical Analysis
Analyses focused on comparing tissue and mechanical valve re-
cipients with respect to changes in QOL scores at 18 months
postoperatively. We also compared baseline and postoperative
QOL scores for patients in the 2 groups with age- and gender-
appropriate US population norms. We defined comparability to US
norms as a postoperative QOL score within one-half a standard
deviation (SD) of the mean of the US norm, a clinically significant
difference as reported in the SF-36 manual.17 In addition, differ-
ences of less than 0.5 SD in magnitude are considered small
according to current recommendations.19 Thus, given these reports
as well as examination of distribution of the responses to QOL
scales reported in the other studies, we considered 0.5 SD differ-
ence as clinically relevant for patients undergoing valve surgery.
We compared unadjusted mean pre- and postoperative QOL
scores in the patients with tissue and mechanical valve replace-
ment with US population norms using 95% confidence intervals of
pre- and postoperative mean QOL scores. We had over 95% power
to demonstrate a 0.5 SD difference as statistically significant with
95% confidence.
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and mechanical valve recipients using the Student t test for means
and chi-square tests for proportions. Multivariable analysis of
covariance was used to examine differences in mean changes in
each of the QOL domains between patients receiving tissue and
mechanical implants. In addition to the inclusion of age and
gender, baseline QOL scores and NYHA functional class were the
strongest predictors of changes in QOL scores and were included
as covariates in the model. Other clinical characteristics were
chosen on the basis of large differences in their distribution in the
tissue and mechanical implant groups; these included the proce-
dure type (isolated valve or simultaneous valve and CABG),
presence of aortic stenosis, history of MI and PVD. We had 80%
power to determine a 0.5 SD difference as statistically significant
with 95% confidence when comparing tissue and mechanical im-
plant groups regarding improvement in QOL.
We used the Statistical Analysis System (SAS Institute, Cary,
NC, release 8.02) for data management and analysis.
Results
Of the 189 consecutive patients undergoing aortic valve
replacement surgery during the study period, 148 (78.3%)
completed a baseline QOL questionnaire. Reasons for non-
participation included death (n  8), language barrier (n 
3), refusal (n  8), neurological problems (n  6), inability
to administer the QOL questionnaire before discharge (n 
TABLE 1. Baseline characteristics of tissue and mechan-
ical implant recipients
Characteristic
Tissue
implant
(n  73)
Mechanical
implant
(n  53) P value
Age (mean  SD) 72.8 11.3 57.8 13.9 .0001
Interquartile range 71-79 47-68
EF (mean)* 48.7 14.7 54.5 11.7 .028
Male gender (%) 54.8 60.4 .5
Having angina 50.7 47.2 .7
History of MI (%) 32.9 17.0 .045
History of CHF (%) 20.8 26.4 .5
Hypertension (%) 65.7 51.9 .12
PVD (%) 21.9 5.7 .012
COPD (%) 16.4 20.7 .5
Diabetes (%) 17.8 15.1 .7
Cardiomegaly (%) 41.1 34.0 .4
Reoperation (%) 11.0 18.8 .2
Arrhythmia (%)† 24.7 30.2 .45
Aortic stenosis (%) 93.1 62.3 .0001
NYHA class III-IV‡ 67.1 41.5 .003
Valve  CABG 49.3 28.3 .017
SD, Standard deviation; CABG, coronary artery bypass graft surgery; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease; EF,
ejection fraction; MI, myocardial infarction; NYHA, New York Heart Asso-
ciation; PVD, peripheral vascular disease.
*Twelve missing values.
†Mostly atrial fibrillation.
‡Compared with I-II functional class.5), and other reasons (n  11). There were no significant
268 The Journal of Thoracic and Cardiovascular Surgery ● Augudifferences between the participants and nonparticipants
with regard to age, gender, or type of implant (data not
shown). Of the 148 patients enrolled, 11 (tissue valve pa-
tients) died before 18 months of follow-up. In the remaining
137 patients, the follow-up rate was 91.9% (126/137). Three
patients refused to complete the QOL questionnaire postop-
eratively, 5 were lost to follow-up, and 3 did not return the
questionnaire within the allotted 6-week time period. Thus,
126 patients (73 [96% follow-up] with tissue and 53 [87%
follow-up] with mechanical implants) had both baseline and
postoperative QOL assessments.
As shown in Table 1, patients receiving tissue implants
were older than those receiving mechanical implants (mean
age 73 years vs 58 years) and they had more comorbidities.
Differences in age and comorbidities between patients with
tissue and mechanical implants were reflected in the mean
unadjusted baseline QOL scores. As shown in Table 2,
unadjusted mean baseline QOL scores tended to be lower in
patients with tissue implants and were significantly lower
than those of patients with mechanical implants for the
domains of PF, RP, and PCS.
In both groups, QOL at 18 months after surgery was
substantially improved in most domains. Trends in absolute
improvements (unadjusted) in QOL scores from the base-
line were similar in the tissue and mechanical valve groups
(Table 2 and Figures 1 and 2). The few domains in which
there seemed to be very little absolute improvement from
baseline included GH and RE in the tissue implant group
and GH in the mechanical implant group. In the domains of
TABLE 2. Baseline QOL scores and unadjusted improve-
ments in QOL domains and component scales for tissue
and mechanical implant recipients at 18 months following
surgery
QOL
scales
Tissue implant Mechanical implant
Baseline
scores*
Unadjusted
improvement
Baseline
scores*
Unadjusted
improvement
PF 46.2 27.5 20.1 59.4 30.0 19.6
RP 20.7 34.9 29.0 36.5 42.4 43.3
BP 64.6 30.6 10.9 67.6 28.9 17.9
GH 55.7 12.4 2.6 57.6 12.7 2.2
VT 38.3 20.7 15.8 45.7 24.9 17.0
SF 69.5 25.2 9.9 75.9 26.6 8.5
RE 62.0 45.2 1.9 59.6 45.9 18.6
MH 57.7 12.6 18.7 58.6 10.7 16.8
PCS 35.8 9.2 6.9 40.5 9.6 8.6
MCS 43.0 9.0 4.8 43.1 8.2 4.9
BP, Bodily Pain; GH, General Health; MCS, Mental Component Summary;
MH, Mental Health; PCS, Physical Component Summary; PF, Physical
Functioning; QOL, quality of life; RE, Role Emotional; RP, Role Physical; SF,
Social Functioning; VT, Vitality.
There were less than 3% missing values for some of the scales.
*Unadjusted baseline scores (mean  SD).RP and RE, there was a tendency toward greater improve-
st 2004
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CDFigure 1. Unadjusted QOL scores with 95% confidence intervals in patients receiving tissue implants. White boxes
represent preoperative QOL scores, white circles represent 18-month follow-up QOL scores, and black triangles
represent US age-adjusted population norms for tissue implant group. BP, Bodily Pain; GH, General Health; MCS,
Mental Component Summary; MH, Mental Health; PCS, Physical Component Summary; PF, Physical Functioning;
QOL, quality of life; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.Figure 2. Unadjusted QOL scores with 95% confidence intervals in patients receiving mechanical implants. White
boxes represent preoperative QOL scores, white circles represent 18-month follow-up QOL scores, and black
triangles represent US age-adjusted population norms for mechanical implant group. BP, Bodily Pain; GH, General
Health; MCS, Mental Component Summary; MH, Mental Health; PCS, Physical Component Summary; PF, Physical
Functioning; QOL, quality of life; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.
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implants compared with those receiving tissue implants
(Table 2). However, these differences in absolute improve-
ments were less than 0.5 SD.
At baseline, both the tissue and mechanical implant
groups tended to have lower mean QOL scores in most
domains relative to their respective US population norms.
Exceptions included the BP and GH scales in the tissue
implant group and the BP, GH, and SF scales in the me-
chanical implant group, which were comparable to those of
population norms (Figures 1 and 2). In contrast, postoper-
ative QOL scores in both groups were similar to US popu-
lation norms and in some instances were higher.
After adjusting for preoperative QOL scores, age, gen-
der, history of MI, PVD, NYHA class, aortic stenosis, and
procedure type (isolated valve or simultaneous valve and
CABG), improvements in mean QOL scores for the tissue
and mechanical implant groups were still similar. The only
exception was for the RP domain, in which improvement
was more favorable in the mechanical implant group (Table
3).
Discussion
In this study, we found that improvements in QOL from the
TABLE 3. Adjusted improvements from the baseline in QOL
domains and component scales for tissue and mechanical
implant recipients at 18 months following surgery
QOL
scales
Tissue
implant
Mechanical
implant
Difference
(mean, 95% CI) P*
PF 16.7 19.2 2.5 (13.1-8.0) .6
RP 21.3 38.3 17.0 (33.8-0.34) .046
BP 4.8 11.8 7.0 (17.1-3.1) .2
GH 0.5 1.3 0.8 (4.4-2.8) .6
VT 9.9 10.1 0.1 (9.4-9.1) 1.0
SF 0.9 0.8 1.7 (11.7-8.2) .7
RE 2.1 5.5 7.6 (24.2-8.9) .4
MH 18.2 16.5 1.8 (5.7-9.2) .6
PCS 4.2 7.3 3.1 (6.7-0.5) .1
MCS 3.3 2.5 0.8 (3.5-5.1) .7
BP, Bodily Pain; CI, confidence interval; GH, General Health; MCS, Mental
Component Summary; MH, Mental Health; PCS, Physical Component Sum-
mary; PF, Physical Functioning; QOL, quality of life; RE, Role Emotional; RP,
Role Physical; SF, Social Functioning; VT, Vitality.
Note. Least-square means presented here are useful measures for QOL
score comparisons but not for evaluation of absolute QOL improvements.
Unadjusted improvements from baseline shown in Table 2 and Figures 1
and 2 should be used for the evaluation of absolute improvements. Im-
provements are based on analysis of covariance (least square means)
model adjusting for the baseline score, age, gender, history of myocardial
infarction, peripheral vascular disease, New York Heart Association class,
aortic stenosis, and the procedure type (isolated valve or simultaneous
valve and coronary artery bypass graft surgery).
*P value for the difference between the least-square means.baseline at 18 months following aortic valve surgery were
270 The Journal of Thoracic and Cardiovascular Surgery ● Augusimilar in patients receiving tissue and mechanical valve
implants. In addition, although the mean scores before sur-
gery for both groups were lower relative to US population
norms, at 18 months after surgery they were greatly im-
proved and generally comparable to US population norms.
Our results are generally consistent with and extend the
findings of previous studies that have examined QOL scores
in patients receiving tissue and mechanical implants or that
made comparisons of preoperative and postoperative QOL
scores in patients undergoing valve replacements with those
of population norms. Phillips and Lansky16 were the first to
demonstrate that in both tissue and mechanical valve recip-
ients, preoperative QOL scores were generally lower than in
population norms, whereas by 6 months postoperatively, the
scores had improved and approximated those of the general
population. However, that study was small and had a low
follow-up rate, which resulted in power limitations that
prevented analyses by type of valve implant. Other cross-
sectional studies have confirmed the finding that tissue and
mechanical implant recipients have similar QOL scores
following aortic valve surgery.6,7 Finally, a prospective
study9 addressing change in QOL at 3 months postopera-
tively found no differences in improvements in QOL scores
reported by tissue and mechanical valve recipients. Al-
though these individual studies had a number of limitations
including significant losses to follow-up,16 inconsistent time
of QOL assessment postsurgery,7 and small sample size,9
the consistency of the results in a variety of study designs
supports the validity of the findings in the current largest
prospective study to date.
In our study, although mechanical implant recipients
reported greater improvement in the scale of RP (resulting
in a trend toward slightly more improvements in PCS),
postoperative scores for this scale as well as for others were
similar to age-adjusted population norms in both the tissue
and mechanical implant groups. Moreover, in the multi-item
scales of PF, VT, and MH, as well as in the global physical
(PCS) and mental (MCS) component scales, we found no
statistically significant differences between the groups. Fi-
nally, tissue valve implant recipients were much more likely
to be elderly and, despite statistical adjustment for age,
possible residual confounding should favor mechanical
valve implant recipients. Thus, the evidence of similar QOL
benefits after tissue valve implantation is even stronger
when taking into account that some small differences in
QOL could potentially be age-related.
Clinical decisions regarding whether to use a tissue or a
mechanical implant for aortic valve replacement are based
primarily on weighing the anticoagulant-related complica-
tions of mechanical implants with the shorter implant life
span of tissue implants. Lifelong anticoagulation with war-
farin and international normalized ratio monitoring is re-
quired in patients receiving mechanical implants. The asso-
st 2004
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from 1.4% to 6.5% per year and bleeding that varies from
0.7% to 4.8% per year.20 In contrast, thromboembolic
events in tissue implant patients are lower (0.2%-2.6% per
year) and bleeding is rare.20 The major disadvantage of
tissue implants is valve deterioration that results in reopera-
tion. Although recent randomized trials have shown that the
incidence of primary valve failure is similar in the 2 types of
implants for up to 10 years, by 12 years the proportion of
patients requiring reoperation is higher in tissue implant
recipients.21,22 For elderly patients (over 70 years) or very
high-risk patients, the choice of the type of implant should
be considered less of an issue, as the probability of outliving
a tissue implant is less. Further, bleeding associated with
mechanical implants has been shown to be more common in
the elderly, exceeding 5.6% per year,23,24 and resulting in a
greater than 50% cumulative risk of experiencing a major
bleed at 10 years.
Strengths and Limitations
The strengths of our study include the prospective cohort
design, a relatively large sample size, and control for po-
tential confounding variables. We examined QOL at 18
months postoperatively, thus assessing longer-term fol-
low-up than has previously been addressed. We assessed
QOL with the SF-36 questionnaire, a validated and widely
used instrument. Furthermore, there was no age exclusion
and older individuals were well represented. Thus, the re-
sults of our study are generalizable to elderly patients, who
comprise the majority of patients undergoing aortic valve
replacement. In this study we had sufficient power to de-
termine statistical significance (with 95% confidence) of a
clinically relevant 0.5 SD difference between the valve
implant groups. The confidence intervals around the esti-
mate of the difference in QOL between the 2 types of valves
were not large (less than 1 SD), which supports the robust-
ness of our findings.
There are issues that should be considered in the inter-
pretation of the results. Baseline QOL data were obtained
during the first week after surgery. However, patients were
asked to report their QOL in the month before surgery and
we do not expect there to be differential recall bias based on
the type of valve implant. We collected postoperative QOL
assessments on 92% of the enrolled patients who survived
to 18 months. However, 11 patients, all of whom were tissue
implant recipients, died prior to 18 months of follow-up. A
possible limitation of our study is that patients in the tissue
implant group who died may have differed with regard to
change in QOL scores compared with those who survived
and were included in the change analysis. The differences in
mortality between the treatment groups may reflect the older
age (means: 73 versus 58 years) of the patients who re-
ceived tissue valves, as these valves are more frequently
The Journal of Thoraciselected for older patients. We did not have sufficient power
to investigate mortality in this study. Age was a relatively
insignificant predictor of change in QOL; however, despite
some recent encouraging reports of acceptable operative
mortality in the elderly, age is still one of the main predic-
tors of early and late mortality after valve surgery.22,25
Finally, we determined QOL at 1.5 years following surgery,
and although it is the longest follow-up in the literature to
date, longer-term follow-up is indicated.
Conclusions
QOL scores for both tissue and mechanical valve recipients
improved from baseline to 18 months postsurgery to a level,
on average, comparable to population norms. Improvements
in QOL appear to be similar with the 2 types of implants.
These findings suggest that surgeons should continue to
make decisions about whether to choose a tissue or mechan-
ical valve implant based on factors such as the possible need
for reoperation and expected tolerance of anticoagulation.
The Center for Outcomes Research and Evaluation (CORE) of
Yale-New Haven Hospital collected detailed baseline demo-
graphic and clinical information for this study. We thank Maria
Johnson for her excellent editorial work.
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